Business Context and Reporting Period
Company: Nurix Therapeutics, Inc. (NRIX)
Filing Type: Form 8-K (Current Report)
Date of Report: July 8, 2021
Event: Entry into a Material Definitive Agreement (Lease)
Key Financial Metrics
This filing does not report revenue, profit, cash flow, margins, debt, or liquidity metrics. It discloses specific lease obligations:
- Monthly Minimum Rent: Approximately $115,920 (commencing December 1, 2021).
- Rent Escalation: 3% annual increase over the lease term.
- Additional Costs: Company responsible for share of operating expenses, taxes, and utilities.
Material Changes
The Company entered into a lease agreement with ARE-San Francisco No. 19, LLC for approximately 19,320 square feet of office space at 455 Mission Bay Boulevard South, San Francisco, California. The space is designated for research and development laboratory use. The lease term runs from the expected commencement date of December 1, 2021, through June 30, 2024.
Outlook, Risks, and Management Commentary
The lease agreement is effective as of June 21, 2021, with occupancy expected to begin in December 2021. The full text of the lease will be filed as an exhibit to the Company's Quarterly Report on Form 10-Q for the quarter ending August 31, 2021. No specific risks or contingencies beyond the standard lease obligations were detailed in this summary.
Investor Verification Checklist
- Verify the total committed lease obligation over the term (approx. 30 months).
- Confirm the exact square footage and specific R&D capabilities of the new facility.
- Review the upcoming Form 10-Q (Q2 2021) for the full lease agreement text and any additional financial covenants.
- Assess the impact of the new monthly rent on the Company's current cash burn rate.